Design and Rationale of the Cognitive Intervention to Improve Memory in Heart Failure Patients Study

Susan J Pressler1, Bruno Giordani, Marita Titler

  • 1Susan J. Pressler, PhD, RN Director, Center for Enhancing Quality of Life in Chronic Illness, and Professor and Sally Reahard Chair, Indiana University School of Nursing, Indianapolis. Bruno Giordani, PhD Professor, Neuropsychology Program, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor. Marita Titler, PhD, RN Professor, Rhetaugh Dumas Endowed Chair, and Department Chair, Systems, Populations and Leadership, University of Michigan School of Nursing, Ann Arbor. Irmina Gradus-Pizlo, MD Clinical Professor, Division of Cardiology, University of California, Irvine. Dean Smith, PhD Professor and Dean, School of Public Health, Louisiana State University Health Sciences Center, New Orleans. Susan G. Dorsey, PhD, RN Professor and Department Chair, Department of Pain and Transitional Symptom Science, University of Maryland School of Nursing, Baltimore. Sujuan Gao, PhD Professor, Department of Biostatistics, Indiana University School of Medicine, Indianapolis. Miyeon Jung, PhD, RN Assistant Professor, Indiana University School of Nursing, Indianapolis.

Insights

This study investigated BrainHQ, a computerized cognitive training program, for heart failure patients experiencing memory loss. Results will inform new therapeutic approaches for this common comorbidity.

Area of Science:

  • Neurology
  • Cardiology
  • Gerontology

Background:

  • Memory loss is prevalent in heart failure patients, predicting mortality.
  • Few effective interventions exist for cognitive impairment in heart failure.
  • This study addresses a critical unmet need in heart failure management.

Purpose of the Study:

  • To evaluate the efficacy of computerized cognitive training (BrainHQ) for memory and neurotrophic factor improvement in heart failure patients.
  • To assess the cost-effectiveness of the BrainHQ intervention.
  • To explore the influence of depressive symptoms and genetics on BrainHQ's effectiveness.

Main Methods:

  • A 3-arm randomized controlled trial involving 264 heart failure patients.
  • Participants assigned to BrainHQ, crossword puzzles (active control), or usual care.
  • Data collected at baseline, 10 weeks, 4 months, and 8 months, with intent-to-treat analysis.

Main Results:

  • This section is not available in the provided abstract.

Conclusions:

  • The research will yield novel insights into BrainHQ's potential to enhance memory and brain-derived neurotrophic factor in heart failure.
  • If effective, BrainHQ offers a disseminable therapeutic strategy for a significant heart failure comorbidity.
Abstract

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
545
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
164
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395